The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Status:
Not yet recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
The study will be a Prospective, Single-arm, Phase Ⅱ Clinical Study. This study intends to
explore the efficacy and safety of Fuzuloparib combined with bevacizumab in the maintenance
treatment of patients with platinum-sensitive ovarian cancer. The progression-free survival,
OS, and safety were evaluated based on RECIST V1.1.